Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences, Icon Ink Biomarker Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Irish biotech and pharmaceutical services firm Icon and Proteome Sciences have agreed to collaborate to offer a biomarker discovery solution to assess new candidate drugs, Icon said today.

Under the agreement, Proteome Sciences' PS Biomarker Services business will expand Icon's biomarker solution to include an integrated suite of labeling, separation, and mass spectrometry tools for use in peptide profiling in complex biological materials. Icon said it is already working with Proteome Sciences under a joint project to develop a mass spectrometry assay for a biomarker for a pharmaceutical development company.

Icon's VP of Biomarker Lab Services, John Allison, said in a statement that the partnership complement's the firm's "portfolio of biomarker development and analysis services to help sponsor identify, implement, and interpret the right biomarkers to inform their pre-clinical and clinical drug development."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.